Ocrelizumab significantly reduced the number and volume of cortical lesions associated with multiple sclerosis at 120 weeks, ...

Ocrelizumab treatment in Black and Hispanic patients with MS reduces NfL levels and prevents the forming of contrast-enhancing lesions and new or enlarging T2 lesions.

Ocrevus treatment was linked to increases in myelin and reductions in iron in MS patients with paramagnetic rim lesions, per ...

The study examined four monoclonal antibodies for MS: natalizumab, ocrelizumab, rituximab and ofatumumab. MS is a disease in which the body's immune system attacks myelin, the fatty white ...

Higher ocrelizumab doses improve the benefit-risk profile among patients with relapsing multiple sclerosis treated with it for up to 10 years.

However, as most data is registry-based and previous trials did not directly compare aHSCT with the most efficacious DMTs, Alemtuzumab, Ocrelizumab, Cladribine and Ofatumumab, questions remain over ...